No Data
No Data
Immix Biopharma: Ex-US Study of NXC-201 Produced 92% ORR in R/r AL Amyloidosis
Express News | Immix Biopharma Inc: Now Dosing at Dose Expansion Level of 450 Mln Nxc-201 Car+T Cells
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2
Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
Express News | Immix Biopharma Announces DR. Raymond Comenzo, Internationally Recognized Al Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
Immix Biopharma Independent Director Acquires 2.6% More Stock
No Data
No Data